Cytokinetics Inc (CYTK) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Cytokinetics Inc (NASDAQ:CYTK) is held by 377 institutional firms.

• Institutional ownership in Cytokinetics edged up to 124.0% in September 2025, compared to 115.0% in June 2025.
• Institutional share ownership changed by 6.38% QoQ, while the number of institutional owners saw an increase of 8.02% YoY.
• Of these 377 institutional investors, 193 increased their holdings in Cytokinetics, while 131 of them reduced positions, and 53 investors maintained their exposure.
• The aggregate institutional position in Cytokinetics now stands at 148.35Mn shares as of September 2025, after investors increased their holdings (up by 8.90Mn shares quarter on quarter which is up 11.10Mn shares year over year).
• The top institutional stake in Cytokinetics as of September 30, 2025 belongs to T. Rowe Price Investment Management, Inc., which owns 19.08Mn shares, or 15.95% of the company.
• Among the most significant buyers of Cytokinetics during September 2025 were TUDOR INVESTMENT CORP ET AL (5.93Mn), FMR LLC (1.82Mn), T. Rowe Price Investment Management, Inc. (1.48Mn), Woodline Partners LP (1.44Mn), Deep Track Capital, LP (650.00K).
• Leading sellers of Cytokinetics stock in September 2025 included Vestal Point Capital, LP (2.25Mn), UBS Group AG (1.27Mn), Point72 Asset Management, L.P. (1.25Mn), ALLIANCEBERNSTEIN L.P. (1.15Mn), STATE STREET CORP (755.42K).
• The top 10 institutional holders of Cytokinetics for the quarter ending September 2025 included T. Rowe Price Investment Management, Inc. (19.08Mn), BlackRock, Inc. (15.53Mn), FMR LLC (13.09Mn), VANGUARD GROUP INC (11.86Mn), WELLINGTON MANAGEMENT GROUP LLP (7.41Mn), TUDOR INVESTMENT CORP ET AL (6.00Mn), STATE STREET CORP (5.62Mn), Deep Track Capital, LP (4.30Mn), BANK OF AMERICA CORP /DE/ (3.06Mn), GEODE CAPITAL MANAGEMENT, LLC (3.04Mn).